Risk factor
Very poor trading liquidity
Profitability factor
Very low or no dividends
About
Malin Corporation plc operates as a life sciences firm across Ireland and the United States, primarily through its various subsidiaries. The company specializes in developing and delivering vital solutions for critical medical challenges. Its portfolio includes groundbreaking cell and gene therapies aimed at patients with significant unmet medical requirements. Furthermore, Malin provides treatments targeting pressing needs in oncology, infectious diseases, and autoimmune conditions. It also addresses specific women's health concerns, such as recurrent vulvovaginal candidiasis, and offers remedies for fungal nail infections like onychomycosis. Beyond these, Malin's offerings extend to pharmaceutical products for protein misfolding disorders, a sophisticated platform designed to identify pathogenic bacteria within the gut microbiome, and advanced UV-light disinfection technologies. Additionally, it offers corporate secretarial services. Established in 2014, Malin Corporation plc maintains its headquarters in Dublin, Ireland.
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is overpriced on P/E.